Loading...
Market
Story
Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling
Oct 22, 2024, 07:13 PM
Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.
View original story
Similar markets
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Amjevita • 25%
Wezlana • 25%
Other • 25%
None • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10-20% • 25%
21-30% • 25%
More than 30% • 25%